TYCRUVA Trademark

Trademark Overview


On Wednesday, October 7, 2020, a trademark application was filed for TYCRUVA with the United States Patent and Trademark Office. The USPTO has given the TYCRUVA trademark a serial number of 90240882. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Thursday, May 5, 2022. This trademark is owned by Bristol-Myers Squibb Company. The TYCRUVA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
tycruva

General Information


Serial Number90240882
Word MarkTYCRUVA
Filing DateWednesday, October 7, 2020
Status730 - FIRST EXTENSION - GRANTED
Status DateThursday, May 5, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 14, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing
Translation of Words in MarkThe word(s) "TYCRUVA" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, November 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Saturday, May 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 5, 2022SOU EXTENSION 1 GRANTED
Thursday, May 5, 2022SOU EXTENSION 1 FILED
Thursday, May 5, 2022TEAS EXTENSION RECEIVED
Tuesday, November 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021PUBLISHED FOR OPPOSITION
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, August 6, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 6, 2021EXAMINER'S AMENDMENT ENTERED
Friday, August 6, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, August 6, 2021EXAMINERS AMENDMENT E-MAILED
Friday, August 6, 2021EXAMINERS AMENDMENT -WRITTEN
Tuesday, July 27, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, January 28, 2021NON-FINAL ACTION E-MAILED
Thursday, January 28, 2021NON-FINAL ACTION WRITTEN
Wednesday, January 27, 2021ASSIGNED TO EXAMINER
Saturday, November 21, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, October 10, 2020NEW APPLICATION ENTERED IN TRAM